Einzeltreffer — DigiBib

Left ventricular hypertrophy (LVH) is a hypertensive heart disease that significantly escalates the risk of clinical cardiovascular events. Its etiology potentially incorporates various clinical attributes such as gender, age, and renal function. From mechanistic perspective, the remodeling process of LVH can trigger increment in certain biomarkers, notably sST2 and NT-proBNP. This multicenter, retrospective study aimed to construct an LVH risk assessment model and identify the risk factors. A total of 417 patients with essential hypertension (EH), including 214 males and 203 females aged 31-80 years, were enrolled in this study; of these, 161 (38.6%) were diagnosed with LVH. Based on variables demonstrating significant disparities between the LVH and Non-LVH groups, three multivariate stepwise logistic regression models were constructed for risk assessment: the "Clinical characteristics" model, the "Biomarkers" model (each based on their respective variables), and the "Clinical characteristics + Biomarkers" model, which amalgamated both sets of variables. The results revealed that the "Clinical characteristics + Biomarkers" model surpassed the baseline models in performance (AUC values of the "Clinical characteristics + Biomarkers" model, the "Biomarkers" model, and the "Clinical characteristics" model were .83, .75, and .74, respectively; P < .0001 for both comparisons). The optimized model suggested that being female (OR: 4.26, P <.001), being overweight (OR: 1.88, p = .02) or obese (OR: 2.36, p = .02), duration of hypertension (OR: 1.04, P = .04), grade III hypertension (OR: 2.12, P < .001), and sST2 (log-transformed, OR: 1.14, P < .001) were risk factors, while eGFR acted as a protective factor (OR: .98, P = .01). These findings suggest that the integration of clinical characteristics and biomarkers can enhance the performance of LVH risk assessment.

Titel:	Nomogram-based risk assessment model for left ventricular hypertrophy in patients with essential hypertension: Incorporating clinical characteristics and biomarkers.
Autor/in / Beteiligte Person:	Wang, CC ; Liang, LK ; Luo, SM ; Wang, HC ; Wang, XL ; Cheng, YH ; Pan, GM ; Peng, JY ; Han, SJ ; Wang, X
Zeitschrift:	Journal of clinical hypertension (Greenwich, Conn.), Jg. 26 (2024-04-01), Heft 4, S. 363-373
Veröffentlichung:	<Sept. 2008-> : [Hoboken, NJ] : Wiley Periodicals Inc. ; <i>Original Publication</i>: Greenwich, CT : Le Jacq Communication, Inc., c1999-, 2024
Medientyp:	academicJournal
ISSN:	1751-7176 (electronic)
DOI:	10.1111/jch.14786
Schlagwort:	Female Humans Male Biomarkers Essential Hypertension complications Essential Hypertension epidemiology Nomograms Retrospective Studies Risk Assessment Adult Middle Aged Aged Aged, 80 and over Hypertension complications Hypertension diagnosis Hypertension epidemiology Hypertrophy, Left Ventricular diagnosis Hypertrophy, Left Ventricular epidemiology Hypertrophy, Left Ventricular etiology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Multicenter Study; Journal Article Language: English [J Clin Hypertens (Greenwich)] 2024 Apr; Vol. 26 (4), pp. 363-373. <i>Date of Electronic Publication: </i>2024 Mar 02. MeSH Terms: Hypertension* / complications ; Hypertension* / diagnosis ; Hypertension* / epidemiology ; Hypertrophy, Left Ventricular* / diagnosis ; Hypertrophy, Left Ventricular* / epidemiology ; Hypertrophy, Left Ventricular* / etiology ; Female ; Humans ; Male ; Biomarkers ; Essential Hypertension / complications ; Essential Hypertension / epidemiology ; Nomograms ; Retrospective Studies ; Risk Assessment ; Adult ; Middle Aged ; Aged ; Aged, 80 and over References: J Echocardiogr. 2021 Jun;19(2):71-79. (PMID: 33460030) ; Rev Esp Cardiol. 2006 Feb;59(2):136-42. (PMID: 16540035) ; J Clin Med. 2023 Feb 24;12(5):. (PMID: 36902605) ; Nutr Metab Cardiovasc Dis. 2013 Aug;23(8):771-5. (PMID: 22770750) ; J Hum Hypertens. 2014 Jul;28(7):432-7. (PMID: 24401951) ; Prog Cardiovasc Dis. 2018 Nov - Dec;61(5-6):446-455. (PMID: 30408469) ; Malays Fam Physician. 2012 Aug 31;7(2-3):2-9. (PMID: 25606250) ; Card Fail Rev. 2020 Mar 16;6:1-7. (PMID: 32257387) ; Ann Noninvasive Electrocardiol. 2019 Jul;24(4):e12635. (PMID: 30719815) ; Front Cardiovasc Med. 2022 Dec 20;9:1082008. (PMID: 36606285) ; Cardiovasc Diagn Ther. 2020 Apr;10(2):296-304. (PMID: 32420112) ; J Am Soc Nephrol. 2012 Oct;23(10):1725-34. (PMID: 22935481) ; Tunis Med. 2019 Feb;97(2):335-343. (PMID: 31539092) ; J Clin Hypertens (Greenwich). 2015 Nov;17(11):874-9. (PMID: 26075863) ; J Electrocardiol. 2022 Jul-Aug;73:153-156. (PMID: 35718553) ; J Thromb Thrombolysis. 2020 Feb;49(2):177-183. (PMID: 31898271) ; Prog Cardiovasc Dis. 2020 Jan - Feb;63(1):10-21. (PMID: 31759953) ; Int J Gen Med. 2020 Nov 27;13:1297-1304. (PMID: 33273849) ; J Clin Hypertens (Greenwich). 2023 Oct 4;:. (PMID: 37794691) ; J Clin Hypertens (Greenwich). 2024 Apr;26(4):363-373. (PMID: 38430459) ; Clin Exp Hypertens. 2018;40(4):318-323. (PMID: 28949780) ; J Am Coll Cardiol. 2019 Oct 29;74(17):2193-2203. (PMID: 31648713) ; Int J Cardiol. 2018 May 1;258:257-261. (PMID: 29544940) ; Hypertension. 2006 May;47(5):881-6. (PMID: 16585414) ; Hypertens Res. 2023 Jan;46(1):253-260. (PMID: 36319736) ; Eur J Prev Cardiol. 2013 Oct;20(5):854-61. (PMID: 22556375) ; J Hum Hypertens. 2012 Jun;26(6):343-9. (PMID: 22113443) ; Dis Markers. 2017;2017:2714095. (PMID: 28566800) ; Diabetes Care. 2002 Nov;25(11):1909-13. (PMID: 12401731) ; Am J Hypertens. 2017 Sep 1;30(9):914-922. (PMID: 28430947) ; Int J Biochem Cell Biol. 2019 Nov;116:105619. (PMID: 31561019) ; Curr Hypertens Rep. 2020 Feb 3;22(2):11. (PMID: 32016791) ; Toxins (Basel). 2020 Mar 05;12(3):. (PMID: 32150864) ; J Clin Hypertens (Greenwich). 2021 Jun;23(6):1176-1185. (PMID: 33769693) ; G Ital Cardiol (Rome). 2018 Nov;19(11 Suppl 1):3S-73S. (PMID: 30520455) ; ESC Heart Fail. 2023 Feb;10(1):303-310. (PMID: 36210061) ; Lancet. 2018 Nov 10;392(10159):1923-1994. (PMID: 30496105) ; J Hypertens. 2011 Sep;29(9):1829-36. (PMID: 21799444) ; Ann Noninvasive Electrocardiol. 2021 Nov;26(6):e12863. (PMID: 34114298) ; Pediatr Cardiol. 2024 Mar;45(3):640-647. (PMID: 36988707) Grant Information: 202201020318 Guangzhou Municipal Science and Technology Project Contributed Indexing: Keywords: biomarker; clinical characteristics; essential hypertension; left ventricular hypertrophy; soluble ST2 Substance Nomenclature: 0 (Biomarkers) Entry Date(s): Date Created: 20240302 Date Completed: 20240412 Latest Revision: 20240426 Update Code: 20240426 PubMed Central ID: PMC11007794

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Nomogram-based risk assessment model for left ventricular hypertrophy in patients with essential hypertension: Incorporating clinical characteristics and biomarkers.